In the latest trading session, 1.1 million Neumora Therapeutics Inc (NASDAQ:NMRA) shares changed hands as the company’s beta touched 3.86. With the company’s most recent per share price at $2.22 changing hands around $0.01 or 0.68% at last look, the market valuation stands at $359.47M. NMRA’s current price is a discount, trading about -845.95% off its 52-week high of $21.00. The share price had its 52-week low at $1.83, which suggests the last value was 17.57% up since then. When we look at Neumora Therapeutics Inc’s average trading volume, we note the 10-day average is 10.26 million shares, with the 3-month average coming to 2.61 million.
Analysts gave the Neumora Therapeutics Inc (NMRA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.44. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NMRA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Neumora Therapeutics Inc’s EPS for the current quarter is expected to be -0.37.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Instantly NMRA is in green as seen in intraday trades today. With action 2.53%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -79.01%, with the 5-day performance at 2.53% in the green. However, in the 30-day time frame, Neumora Therapeutics Inc (NASDAQ:NMRA) is -78.59% down. Looking at the short shares, we see there were 10.83 million shares sold at short interest cover period of 11.14 days.
The consensus price target for the stock as assigned by Wall Street analysts is 13.5, meaning bulls need an upside of 83.56% from its recent market value. According to analyst projections, NMRA’s forecast low is 4 with 23 as the target high. To hit the forecast high, the stock’s price needs a -936.04% plunge from its current level, while the stock would need to soar -80.18% for it to hit the projected low.
Neumora Therapeutics Inc (NMRA) estimates and forecasts
Data shows that the Neumora Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -79.86% over the past 6 months, a 55.65% in annual growth rate that is considerably higher than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Neumora Therapeutics Inc earnings to increase by 55.97%.
NMRA Dividends
Neumora Therapeutics Inc is expected to release its next quarterly earnings report in February.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 27.47% of Neumora Therapeutics Inc shares while 64.29% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.64%.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 2.39 shares estimated at $5.25 million under it, the former controlled 1.48% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.34% of the shares, roughly 2.16 shares worth around $4.75 million.
